Floatz Rating
C39/100
Confidence
Indicative
Sponsor
The Medical Pavilion Bahamas
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05515419CT.gov Allogeneic Cord Blood for Neurological Diseases in Adults | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Spinal Cord Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Umbilical Cord Blood (this asset) | The Medical Pavilion Bahamas | Early P1 | C · 39 |
| Pregabalin | Ju Seok Ryu | P4 | BBB |
| Gabapentin | MetroHealth Medical Center | P4 | BB |
| VENLOR | University of Washington | P4 | BB |
| Semaglutide | James J. Peters Veterans Affairs Medical Center | P4 | BB |
| Amitriptyline | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | P4 | BB |
| Brivaracetam | University of Minnesota | P3 | BB |
| Lidocaine | University of Texas Rio Grande Valley | P2 | BB |
| Nabilone | Eldon Loh, MD | P3 | BB |
+34 more in the Spinal Cord Injury cohort
Other indications for Allogeneic Umbilical Cord Blood
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P1 | CC · 43 |
| Nervous System Disorder | — | Early P1 | C · 39 |
| Traumatic Brain Injury | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Umbilical Cord Blood in Spinal Cord Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-umbilical-cord-blood-spinal-cord-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →